1. Home
  2. MESO
  3. MESO News

Latest Mesoblast Limited (MESO) News on August 3, 2025

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
MESO

GlobeNewswire

2 months ago

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval
MESO

Simply Wall St.

2 months ago

Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval

MESO

MT Newswires

3 months ago

Mesoblast Receives 7-Year FDA Orphan Drug Exclusivity for Ryoncil in Pediatric Inflammatory Disease

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®
MESO

GlobeNewswire

3 months ago

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

Mesoblast Limited's (ASX:MSB) market cap dropped AU$96m last week; Individual investors bore the brunt
MESO

Simply Wall St.

3 months ago

Mesoblast Limited's (ASX:MSB) market cap dropped AU$96m last week; Individual investors bore the brunt

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
MESO

GlobeNewswire

3 months ago

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
MESO

GlobeNewswire

3 months ago

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

MESO

MT Newswires

4 months ago

Mesoblast Expands Payer Coverage for Ryoncil

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives
MESO

GlobeNewswire

4 months ago

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs
MESO

GlobeNewswire

4 months ago

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure
MESO

GlobeNewswire

4 months ago

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Mesoblast (ASX:MSB) Announces Ryoncil Availability But Sees 15% Price Drop Over Past Week
MESO

Simply Wall St.

4 months ago

Mesoblast (ASX:MSB) Announces Ryoncil Availability But Sees 15% Price Drop Over Past Week

First Three Children to Commence Treatment With Ryoncil®
MESO

GlobeNewswire

4 months ago

First Three Children to Commence Treatment With Ryoncil®

Ryoncil® is Now Available for Purchase in the United States
MESO

GlobeNewswire

4 months ago

Ryoncil® is Now Available for Purchase in the United States

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States
MESO

GlobeNewswire

5 months ago

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
MESO

GlobeNewswire

5 months ago

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall

Mesoblast Limited (MESO): Among the Best Australian Stocks to Buy According to Billionaires
MESO

Insider Monkey

5 months ago

Mesoblast Limited (MESO): Among the Best Australian Stocks to Buy According to Billionaires

MESO

MT Newswires

5 months ago

Mesoblast Joins S&P/ASX 200 Index

Mesoblast Added to S&P/ASX 200 INDEX
MESO

GlobeNewswire

5 months ago

Mesoblast Added to S&P/ASX 200 INDEX

While Mesoblast (ASX:MSB) shareholders have made 667% in 1 year, increasing losses might now be front of mind as stock sheds 8.7% this week
MESO

Simply Wall St.

5 months ago

While Mesoblast (ASX:MSB) shareholders have made 667% in 1 year, increasing losses might now be front of mind as stock sheds 8.7% this week

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter
MESO

GlobeNewswire

5 months ago

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Mesoblast Limited (MESO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
MESO

Zacks

5 months ago

Mesoblast Limited (MESO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Mesoblast Financial Results and Corporate Update Webcast
MESO

GlobeNewswire

5 months ago

Mesoblast Financial Results and Corporate Update Webcast

Dr. Gregory George MD PhD Joins Mesoblast Board
MESO

GlobeNewswire

5 months ago

Dr. Gregory George MD PhD Joins Mesoblast Board

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
MESO

GlobeNewswire

5 months ago

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings
MESO

GlobeNewswire

6 months ago

Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings

Domino's Pizza Enterprises And 2 Other ASX Stocks That Might Be Trading Below Fair Value
MESO

Simply Wall St.

6 months ago

Domino's Pizza Enterprises And 2 Other ASX Stocks That Might Be Trading Below Fair Value

Is Mesoblast Limited (MESO) the Best Long Term ASX Stock to Buy Now?
MESO

Insider Monkey

6 months ago

Is Mesoblast Limited (MESO) the Best Long Term ASX Stock to Buy Now?

High Growth Tech Stocks in Australia Featuring FINEOS Corporation Holdings and Two Others
MESO

Simply Wall St.

6 months ago

High Growth Tech Stocks in Australia Featuring FINEOS Corporation Holdings and Two Others

Is Mesoblast Limited (MESO) One of the Best ASX Stocks to Buy According to Hedge Funds?
MESO

Insider Monkey

6 months ago

Is Mesoblast Limited (MESO) One of the Best ASX Stocks to Buy According to Hedge Funds?

Ryoncil® Commercial Launch Update and Product Pipeline
MESO

GlobeNewswire

6 months ago

Ryoncil® Commercial Launch Update and Product Pipeline

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024
MESO

GlobeNewswire

6 months ago

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024

Why Mesoblast (MESO) Is Among the Best Australian Stocks to Buy Now?
MESO

Insider Monkey

6 months ago

Why Mesoblast (MESO) Is Among the Best Australian Stocks to Buy Now?

3 ASX Growth Stocks With High Insider Ownership Seeing Up To 55% Earnings Growth
MESO

Simply Wall St.

6 months ago

3 ASX Growth Stocks With High Insider Ownership Seeing Up To 55% Earnings Growth

Bullish Mesoblast Insiders Loaded Up On US$145.4m Of Stock
MESO

Simply Wall St.

6 months ago

Bullish Mesoblast Insiders Loaded Up On US$145.4m Of Stock

MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
MESO

Zacks

7 months ago

MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

Exploring 3 High Growth Tech Stocks In Australia
MESO

Simply Wall St.

7 months ago

Exploring 3 High Growth Tech Stocks In Australia

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
MESO

Zacks

7 months ago

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
MESO

Zacks

7 months ago

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease

FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment
MESO

Pharmaceutical Technology

7 months ago

FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges
MESO

Benzinga

7 months ago

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

MESO

MT Newswires

7 months ago

Mesoblast Says Ryoncil Receives FDA Approval for Acute Graft Versus Host Disease; Shares Rise Pre-Bell

Top-Notch Biotech Mesoblast Skyrockets 29% On Immune Condition Approval
MESO

Investor's Business Daily

8 months ago

Top-Notch Biotech Mesoblast Skyrockets 29% On Immune Condition Approval

Mesoblast to be Added to Nasdaq Biotechnology Index
MESO

GlobeNewswire

8 months ago

Mesoblast to be Added to Nasdaq Biotechnology Index

DREAM-HF trial sheds positive light on Revascor for ischemic HF
MESO

Clinical Trials Arena

8 months ago

DREAM-HF trial sheds positive light on Revascor for ischemic HF

3 ASX Growth Companies With Insider Ownership Up To 38%
MESO

Simply Wall St.

8 months ago

3 ASX Growth Companies With Insider Ownership Up To 38%

Mesoblast’s Revascor Therapy Shows Promise in Heart Failure
MESO

TipRanks

8 months ago

Mesoblast’s Revascor Therapy Shows Promise in Heart Failure

MESO

MT Newswires

8 months ago

Mesoblast Says FDA Granted Regenerative Medicine Advanced Therapy Designation for Revascor

Exploring High Growth Tech Stocks in Australia December 2024
MESO

Simply Wall St.

8 months ago

Exploring High Growth Tech Stocks in Australia December 2024

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease
MESO

GlobeNewswire

8 months ago

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

MESO

MT Newswires

8 months ago

Mesoblast Says Revascor Improved Survival in Ischemic Heart Failure Patients

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
MESO

GlobeNewswire

8 months ago

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Mesoblast Limited's (ASX:MSB) 17% gain last week benefited both retail investors who own 54% as well as insiders
MESO

Simply Wall St.

8 months ago

Mesoblast Limited's (ASX:MSB) 17% gain last week benefited both retail investors who own 54% as well as insiders

Mesoblast Issues 2 Million Warrants for Strategic Flexibility
MESO

TipRanks

9 months ago

Mesoblast Issues 2 Million Warrants for Strategic Flexibility

ASX Growth Companies With High Insider Ownership Seeing Up To 61% Earnings Growth
MESO

Simply Wall St.

9 months ago

ASX Growth Companies With High Insider Ownership Seeing Up To 61% Earnings Growth

Three High Growth Tech Stocks in Australia
MESO

Simply Wall St.

9 months ago

Three High Growth Tech Stocks in Australia

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024
MESO

GlobeNewswire

9 months ago

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

When Will Mesoblast Limited (ASX:MSB) Become Profitable?
MESO

Simply Wall St.

9 months ago

When Will Mesoblast Limited (ASX:MSB) Become Profitable?

Mesoblast Advances Cellular Medicines Amid FDA Hopes
MESO

TipRanks

9 months ago

Mesoblast Advances Cellular Medicines Amid FDA Hopes

ASX Growth Companies With High Insider Ownership In October 2024
MESO

Simply Wall St.

10 months ago

ASX Growth Companies With High Insider Ownership In October 2024

3 ASX Growth Companies With Insider Ownership Up To 37%
MESO

Simply Wall St.

10 months ago

3 ASX Growth Companies With Insider Ownership Up To 37%

3 ASX Growth Stocks With Insider Ownership Up To 36%
MESO

Simply Wall St.

10 months ago

3 ASX Growth Stocks With Insider Ownership Up To 36%

Exploring High Growth Tech Stocks In Australia
MESO

Simply Wall St.

10 months ago

Exploring High Growth Tech Stocks In Australia

3 ASX Growth Stocks Insiders Own With Up To 45% Revenue Growth
MESO

Simply Wall St.

10 months ago

3 ASX Growth Stocks Insiders Own With Up To 45% Revenue Growth

ASX Growth Companies With High Insider Ownership For October 2024
MESO

Simply Wall St.

10 months ago

ASX Growth Companies With High Insider Ownership For October 2024

3 High Growth Tech Stocks in Australia to Watch
MESO

Simply Wall St.

10 months ago

3 High Growth Tech Stocks in Australia to Watch

3 ASX Growth Stocks With High Insider Ownership
MESO

Simply Wall St.

10 months ago

3 ASX Growth Stocks With High Insider Ownership

3 ASX Growth Companies With High Insider Ownership And Up To 60% Earnings Growth
MESO

Simply Wall St.

10 months ago

3 ASX Growth Companies With High Insider Ownership And Up To 60% Earnings Growth

Exploring Three High Growth Tech Stocks In Australia
MESO

Simply Wall St.

10 months ago

Exploring Three High Growth Tech Stocks In Australia

3 ASX Growth Companies Insiders Are Investing In
MESO

Simply Wall St.

10 months ago

3 ASX Growth Companies Insiders Are Investing In

ASX Growth Companies With High Insider Ownership In October 2024
MESO

Simply Wall St.

10 months ago

ASX Growth Companies With High Insider Ownership In October 2024

ASX Growth Companies With High Insider Ownership October 2024
MESO

Simply Wall St.

10 months ago

ASX Growth Companies With High Insider Ownership October 2024

3 High Growth ASX Stocks With Significant Insider Ownership
MESO

Simply Wall St.

10 months ago

3 High Growth ASX Stocks With Significant Insider Ownership

Top High Growth Tech Stocks To Watch In Australia October 2024
MESO

Simply Wall St.

10 months ago

Top High Growth Tech Stocks To Watch In Australia October 2024

MESO

MT Newswires

10 months ago

Mesoblast to Issue up to $50 Million of Convertible Notes for Product Launch of Ryoncil on FDA Approval

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
MESO

GlobeNewswire

10 months ago

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

Mesoblast (MESO): Biotechnology Innovator Nearing Critical Milestones for Life-Changing Therapies
MESO

Insider Monkey

10 months ago

Mesoblast (MESO): Biotechnology Innovator Nearing Critical Milestones for Life-Changing Therapies

3 ASX Growth Companies With High Insider Ownership To Watch
MESO

Simply Wall St.

10 months ago

3 ASX Growth Companies With High Insider Ownership To Watch

Is Mesoblast (MESO) The Best Australian Stock To Buy According to Hedge Funds?
MESO

Insider Monkey

a year ago

Is Mesoblast (MESO) The Best Australian Stock To Buy According to Hedge Funds?

Exploring 3 High Growth Tech Stocks in Australia
MESO

Simply Wall St.

a year ago

Exploring 3 High Growth Tech Stocks in Australia

Mesoblast Full Year 2024 Earnings: Misses Expectations
MESO

Simply Wall St.

a year ago

Mesoblast Full Year 2024 Earnings: Misses Expectations

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024
MESO

GlobeNewswire

a year ago

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

Mesoblast Financial Results and Corporate Update Webcast
MESO

GlobeNewswire

a year ago

Mesoblast Financial Results and Corporate Update Webcast

Exploring 3 High Growth Tech Stocks In Australia
MESO

Simply Wall St.

a year ago

Exploring 3 High Growth Tech Stocks In Australia

Investors in Mesoblast (ASX:MSB) have seen impressive returns of 154% over the past year
MESO

Simply Wall St.

a year ago

Investors in Mesoblast (ASX:MSB) have seen impressive returns of 154% over the past year

Mesoblast Insiders Land Bargain With Gains Of US$58m
MESO

Simply Wall St.

a year ago

Mesoblast Insiders Land Bargain With Gains Of US$58m

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024
MESO

GlobeNewswire

a year ago

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

FDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapy
MESO

Pharmaceutical Technology

a year ago

FDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapy

MESO

MT Newswires

a year ago

Mesoblast Says FDA Accepted Resubmitted Biologics License Application for Ryoncil; Shares Rise Pre-Bell

FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
MESO

GlobeNewswire

a year ago

FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Mesoblast begins subject enrolment in Phase III back pain treatment trial
MESO

Clinical Trials Arena

a year ago

Mesoblast begins subject enrolment in Phase III back pain treatment trial

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain
MESO

GlobeNewswire

a year ago

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

July 2024 ASX Leaders With High Insider Ownership And Strong Growth Prospects
MESO

Simply Wall St.

a year ago

July 2024 ASX Leaders With High Insider Ownership And Strong Growth Prospects

Insider-Owned ASX Growth Companies To Watch In July 2024
MESO

Simply Wall St.

a year ago

Insider-Owned ASX Growth Companies To Watch In July 2024

MESO

MT Newswires

a year ago

Mesoblast Resubmits Ryoncil Biologics License Application

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
MESO

GlobeNewswire

a year ago

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates
MESO

Zacks

a year ago

Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week
MESO

GlobeNewswire

a year ago

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

ASX Growth Companies With High Insider Ownership To Watch In June 2024
MESO

Simply Wall St.

a year ago

ASX Growth Companies With High Insider Ownership To Watch In June 2024

Three ASX Growth Companies With High Insider Ownership And Earnings Growth Up To 120%
MESO

Simply Wall St.

a year ago

Three ASX Growth Companies With High Insider Ownership And Earnings Growth Up To 120%

Share on Social Networks: